Evidence map›Paper›PMID 36969495›Full record

ArticleJournal of immunology research2023

Vascular Normalization Was Associated with Colorectal Tumor Regression upon Anti-PD-L1 Combinational Therapy.

Yan Zhang, Jiayan Gao, Yan He, Ziwei Qi, Long Qian, Wanpei Chen, Haiyan Xu, Yanhua Yue, Xunyuan Mao, Shuxin Guo and 5 more

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Yan ZhangThe Aoyang Cancer Institute, The Affiliated Aoyang Hospital of Jiangsu University, Zhangjiagang, 215617 Jiangsu, China.
Jiayan GaoThe Aoyang Cancer Institute, The Affiliated Aoyang Hospital of Jiangsu University, Zhangjiagang, 215617 Jiangsu, China.
Yan HeHematology Center, Cyrus Tang Medical Institute, The Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, 215123 Jiangsu, China.
Ziwei QiHematology Center, Cyrus Tang Medical Institute, The Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, 215123 Jiangsu, China.
Long QianHematology Center, Cyrus Tang Medical Institute, The Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, 215123 Jiangsu, China.
Wanpei ChenHematology Center, Cyrus Tang Medical Institute, The Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, 215123 Jiangsu, China.
Haiyan XuHematology Center, Cyrus Tang Medical Institute, The Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, 215123 Jiangsu, China.
Yanhua YueHematology Center, Cyrus Tang Medical Institute, The Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, 215123 Jiangsu, China.
Xunyuan MaoHematology Center, Cyrus Tang Medical Institute, The Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, 215123 Jiangsu, China.
Shuxin GuoHematology Center, Cyrus Tang Medical Institute, The Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, 215123 Jiangsu, China.
Yan ZhouThe Aoyang Cancer Institute, The Affiliated Aoyang Hospital of Jiangsu University, Zhangjiagang, 215617 Jiangsu, China.
Shuru ZhouThe Aoyang Cancer Institute, The Affiliated Aoyang Hospital of Jiangsu University, Zhangjiagang, 215617 Jiangsu, China.
Songbing QinDepartment of Radiotherapy, The First Affiliated Hospital of Soochow University, Suzhou, 215006 Jiangsu, China.ORCID https://orcid.org/0000-0001-7056-1741
Xueguang ZhangJiangsu Institute of Clinical Immunology & Jiangsu Key Laboratory of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, 215006 Jiangsu, China.ORCID https://orcid.org/0000-0002-3519-4277
Yuhui HuangHematology Center, Cyrus Tang Medical Institute, The Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, 215123 Jiangsu, China.ORCID https://orcid.org/0000-0003-1985-3575
Soochow University · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-PD-L1 therapy exhibits durable efficacy, but only in a small fraction of cancer patients. The immunosuppressive tumor microenvironment (TME) is a crucial obstacle that impedes cancer immunotherapy. Here, we found that anti-PD-L1 therapy coupled with CD4

Indexed as

CD8-Positive T-LymphocytesColorectal NeoplasmsB7-H1 AntigenCombined Modality TherapyHumansImmunotherapyTumor MicroenvironmentB7-H1 Antigen

Identifiers

PMID36969495
PMCPMC10038742
OpenAlexW4327694387

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read21
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.